Hamlet Pharma regains patent rights for BAMLET

Report this content

The board of Hamlet Pharma has decided to accept a proposal from Linnane Pharma to terminate the patent license agreement from May 12, 2020.

Hamlet Pharma AB and Linnane Pharma AB entered into a licensing agreement on 12 May 2020, for the development of BAMLET; a complex formed by bovine alpha-lactalbumin and oleic acid. According to the agreement, Linnane Pharma would under Hamlet Pharma's patents develop the product BAMLET for non-pharmaceutical use. Since then, Linnane Pharma has worked intensively to drive the project forward. However, the board of Linnane Pharma has acknowledged synergies if Hamlet Pharma decides to develop BAMLET as a drug, not least in terms of manufacturing and formulation. The board of Linnane Pharma has therefore proposed that the licensing agreement from 12 May be terminated. The board of Hamlet Pharma has accepted the proposal from Linnane Pharma and thus all rights have been returned to Hamlet Pharma without any compensation to Linnane Pharma.

For more information, please contact

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57


About HAMLET Pharma

HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo.


This information is insider information that Hamlet Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact persons set out above, on September 4, 2020.


Documents & Links